Royal Bank Of Canada Has Lowered Expectations for Incyte (NASDAQ:INCY) Stock Price

Incyte (NASDAQ:INCY) had its price objective cut by Royal Bank Of Canada from $95.00 to $92.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price suggests a potential downside of 8.68% from the company’s current price.

Other analysts have also issued research reports about the company. Piper Sandler upped their target price on Incyte from $102.00 to $110.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Truist Financial set a $103.00 price objective on Incyte in a research note on Wednesday, December 24th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $90.00 price objective on shares of Incyte in a research report on Thursday, January 8th. Wells Fargo & Company reduced their target price on shares of Incyte from $107.00 to $101.00 and set an “equal weight” rating for the company in a report on Wednesday. Finally, Zacks Research lowered shares of Incyte from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Nine investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $103.94.

Incyte Stock Up 1.9%

Shares of Incyte stock opened at $100.75 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 3.13. The stock has a market cap of $20.05 billion, a price-to-earnings ratio of 15.72, a PEG ratio of 0.59 and a beta of 0.82. The firm’s 50-day moving average is $101.75 and its two-hundred day moving average is $93.86. Incyte has a 1 year low of $53.56 and a 1 year high of $112.29.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing the consensus estimate of $1.96 by ($0.16). Incyte had a return on equity of 26.34% and a net margin of 25.03%.The business had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.35 billion. During the same period in the previous year, the company posted $1.43 EPS. Incyte’s revenue for the quarter was up 27.8% on a year-over-year basis. As a group, research analysts expect that Incyte will post 4.86 earnings per share for the current fiscal year.

Insider Activity at Incyte

In other Incyte news, EVP Steven H. Stein sold 20,105 shares of the business’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $102.51, for a total transaction of $2,060,963.55. Following the sale, the executive vice president owned 63,129 shares of the company’s stock, valued at approximately $6,471,353.79. The trade was a 24.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael James Morrissey sold 54,008 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $97.29, for a total transaction of $5,254,438.32. Following the completion of the transaction, the executive vice president directly owned 31,830 shares of the company’s stock, valued at approximately $3,096,740.70. This represents a 62.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 95,225 shares of company stock worth $9,519,745. 17.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Incyte

Several hedge funds have recently made changes to their positions in INCY. Advisors Asset Management Inc. raised its stake in Incyte by 15.2% in the 4th quarter. Advisors Asset Management Inc. now owns 18,094 shares of the biopharmaceutical company’s stock worth $1,787,000 after acquiring an additional 2,383 shares during the last quarter. DRW Securities LLC acquired a new position in shares of Incyte in the fourth quarter valued at about $338,000. Orion Porfolio Solutions LLC raised its stake in shares of Incyte by 5.8% in the fourth quarter. Orion Porfolio Solutions LLC now owns 8,439 shares of the biopharmaceutical company’s stock worth $834,000 after purchasing an additional 465 shares during the last quarter. Cibc World Markets Corp acquired a new stake in shares of Incyte during the fourth quarter worth about $2,269,000. Finally, Triumph Capital Management purchased a new stake in Incyte in the fourth quarter valued at approximately $63,000. 96.97% of the stock is owned by institutional investors and hedge funds.

Key Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Management provided a forward-looking revenue roadmap, outlining 10–13% revenue growth for 2026 and pointing to pipeline expansion and new product launches as growth drivers — this supports a bullish medium-term revenue thesis. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy rating with a $135 target, reflecting conviction in Incyte’s long-term revenue durability and underappreciated pipeline — a catalyst for upside from some institutional investors. Article Title
• Neutral Sentiment: Q4 earnings call and transcript provide detail: revenue grew strongly (quarterly revenue +27.8% y/y and topped estimates) but EPS missed consensus — investors will parse pipeline comments and margin guidance for signs of sustainable profitability. Article Title
• Neutral Sentiment: Incyte sold Wilmington Bracebridge towers to BPG — a non-core real-estate transaction that slightly improves balance-sheet flexibility but is not material to drug revenue. Article Title
• Neutral Sentiment: Reported short-interest data appears anomalous (shows 0 shares / NaN increase and 0.0 days to cover) — treat as unreliable until clarified by exchanges. (Two entries flagged this oddity.)
• Negative Sentiment: EPS missed consensus on the quarter, prompting a gap-down reaction in shares immediately post-earnings — this short-term selling pressure explains much of the intraday volatility. Article Title
• Negative Sentiment: Royal Bank of Canada cut its price target to $92 and moved to “sector perform,” signaling reduced near-term conviction and pressure on sentiment. (Benzinga / TickerReport coverage noted.)
• Negative Sentiment: Regulatory risk: analysts flagged emerging U.S. “Most Favored Nation” drug-pricing policies as a new risk that could pressure profitability and margins over time — a tangible downside catalyst for revenue forecasts. Article Title

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.